Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICRO-K LS vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Hypokalemia prevention or treatment,Diuretic-induced hypokalemia,Digitalis intoxication
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Not applicable (K+ is an electrolyte, not eliminated by first-order kinetics). Clinical context: Serum K+ decline follows redistribution and excretion with a half-life of ~2-4 hours after IV bolus.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Not metabolized; excreted primarily via kidneys.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Renal: ~90% as KCl (proportional to intake). Biliary/fecal: <10%.
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
None (K+ is free ion).
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
0.35 L/kg (approximate total body water; distributes primarily in extracellular fluid).
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Oral: ~80-100% for microencapsulated KCl (MICRO-K), but can be incomplete due to slower release.
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
GFR 50-90 m L/min: no adjustment. GFR 30-49 m L/min: reduce dose by 25-50%. GFR <30 m L/min: avoid use or reduce dose by 50-75% with close monitoring.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: avoid use or reduce dose by 50%.
No adjustment required for hepatic impairment.
1-3 m Eq/kg/day orally in 2-4 divided doses; maximum 1 m Eq/kg per dose and 100 m Eq/day.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Initiate at lower end of dosing range (10-20 m Eq/day); monitor renal function and serum potassium frequently; adjust based on renal function.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
No black box warning.
No FDA black box warning.
Risk of hyperkalemia especially in renal impairment,Use with caution in cardiac disease,GI irritation or ulceration with oral forms,Slow release formulations may cause GI lesions
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia,Severe renal impairment,Untreated Addison's disease,Acute dehydration,Use of potassium-sparing diuretics
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, potatoes, spinach, avocados, dried fruits, salt substitutes containing potassium chloride). Do not take with alcohol as it may increase GI irritation. Grapefruit juice has no significant interaction, but large amounts of any food high in potassium should be avoided.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium is a normal component of breast milk. No adverse effects expected at maternal therapeutic doses. M/P ratio: not applicable (endogenous electrolyte).
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No dose adjustment typically required. Maintain serum potassium within normal range. Monitor for hypokalemia or hyperkalemia as clinically indicated.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
MICRO-K LS contains potassium chloride microencapsulated granules for sustained release. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min), untreated Addison's disease, or hyperkalemia. Use with caution in patients with cardiac disease or concurrent use of ACE inhibitors, ARBs, or potassium-sparing diuretics. Do not crush or chew capsules; administer with a full glass of water to prevent GI mucosal damage. Monitor serum potassium regularly, especially in elderly and diabetic patients.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
Take this medication exactly as prescribed, preferably with meals or a full glass of water.,Do not crush, chew, or break the capsules; swallow them whole.,Avoid foods high in potassium (e.g., bananas, oranges, tomatoes, salt substitutes) unless directed by your doctor.,Contact your doctor immediately if you experience muscle weakness, irregular heartbeat, numbness/tingling, or dark/tarry stools.,Store at room temperature away from moisture and heat.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
No interactions on record
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICRO-K LS vs CALCIUM GLUCONATE, answered by our medical review team.
MICRO-K LS is a Electrolyte Supplement (Potassium) that works by Potassium supplement; replaces intracellular potassium, essential for nerve conduction, muscle contraction, and acid-base balance.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICRO-K LS and CALCIUM GLUCONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICRO-K LS is: 10-20 m Eq (as potassium chloride) orally twice daily; maximum 100 m Eq/day.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICRO-K LS and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICRO-K LS is classified as Category C. MICRO-K LS (potassium chloride) is not associated with teratogenicity. No fetal risks have been reported in any trimester. Use during pregnancy is considered safe when indicated.. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.